MoonLake Immunotherapeutics (NASDAQ:MLTX) shares, rose in value on Wednesday, June 18, with the stock price up by 1.16% to the previous day’s close as strong demand from buyers drove the stock to $43.50.
Actively observing the price movement in the last trading, the stock closed the session at $43.00, falling within a range of $42.93 and $44.195. The value of beta (5-year monthly) was 1.23. Referring to stock’s 52-week performance, its high was $58.26, and the low was $31.42. On the whole, MLTX has fluctuated by 10.97% over the past month.
With the market capitalization of MoonLake Immunotherapeutics currently standing at about $2.79 billion, investors are eagerly awaiting this quarter’s results, scheduled for on 2025-May-12.
Technical indicators serve as essential tools for traders, offering insights into market sentiment and potential price movements. We see that MLTX’s technical picture suggests that short-term indicators denote the stock is a 50% Buy on average. However, medium-term indicators have put the stock in the category of 50% Sell while long-term indicators on average have been pointing out that it is a 50% Sell.
The stock’s technical analysis shows that the price of MLTX currently trading nearly 0.97% and 7.80% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 52.69, while the 7-day volatility ratio is showing 1.85% which for the 30-day chart, stands at 4.69%. Furthermore, MoonLake Immunotherapeutics (MLTX)’s beta value is 1.23, and its average true range (ATR) is 2.20.
A comparison of MoonLake Immunotherapeutics (MLTX) with its peers suggests the former has fared considerably weaker in the market. MLTX showed an intraday change of 1.16% in last session, and over the past year, it grew by 5.05%%.
Data on historical trading for MoonLake Immunotherapeutics (NASDAQ:MLTX) indicates that the trading volumes over the past 10 days have averaged 0.59 and over the past 3 months, they’ve averaged 530.99K. According to company’s latest data on outstanding shares, there are 63.47 million shares outstanding.
Nearly 16.60% of MoonLake Immunotherapeutics’s shares belong to company insiders and institutional investors own 94.66% of the company’s shares. The data on short interest also indicates that stock shorts accounted for 6.31 million shares as on 2025-05-30, resulting in a short ratio of 20.27. According to the data, the short interest in MoonLake Immunotherapeutics (MLTX) stood at 2232.00 of shares outstanding as of 2025-05-30; the number of short shares registered in 2025-04-30 reached 6.1 million. The stock has fallen by -19.67% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the MLTX stock heading into the next quarter.
